Residency · Residency · Nuclear Medicine
F-18 FDG: Production, Biodistribution, and Pitfalls
F-18 Production and FDG Synthesis
Cyclotron Production of F-18
F-18 is produced by bombarding O-18-enriched water with protons in a medical cyclotron, via the nuclear reaction O-18(p,n)F-18. Typical cyclotrons used for this purpose accelerate protons to 11 to 18 MeV. The F-18 emerges as aqueous fluoride ion (F-18 minus) dissolved in the enriched water target. F-18 has a half-life of 109.8 minutes (approximately 2 hours) and decays by positron emission 97% of the time, with 3% by electron capture. The emitted positrons have a maximum energy of 634 keV and a mean range in tissue of approximately 0.6 mm, which gives F-18 the best spatial resolution among clinical PET radionuclides.
FDG Synthesis
FDG -- 2-deoxy-2-[F-18]fluoro-D-glucose -- is synthesized by nucleophilic fluorination of a mannose triflate precursor using automated synthesis modules in commercial radiopharmacies. The synthesis takes approximately 30 to 60 minutes. Before release, the product undergoes rigorous quality control: radiochemical purity must exceed 95% (assessed by HPLC or TLC), radionuclidic purity is confirmed by half-life measurement and gamma spectroscopy, and chemical purity testing checks for residual solvents including acetonitrile (must be below 0.04%) and ethanol, as well as the cryptand Kryptofix 2.2.2 (below 50 micrograms/mL). The pH must fall between 4.5 and 8.5, and the product must pass sterility and endotoxin testing and be visually clear, colorless, and free of particles. FDG is distributed from centralized radiopharmacies to imaging centers and remains viable for use within approximately 4 half-lives of synthesis.
Mechanism of FDG Uptake
Glucose Metabolism Analogy
FDG is a glucose analog in which fluorine replaces the hydroxyl group at the 2-carbon position of the glucose molecule. Like glucose, FDG enters cells through glucose transporters (GLUTs), primarily GLUT-1 and GLUT-3. Once inside the cell, hexokinase phosphorylates FDG to FDG-6-phosphate. However, because FDG lacks the 2-hydroxyl group required for the next step in glycolysis (isomerization by phosphoglucose isomerase), FDG-6-phosphate cannot proceed through further glycolytic metabolism. Moreover, FDG-6-phosphate is not a good substrate for glucose-6-phosphatase in most tissues, so it cannot be dephosphorylated and exported from the cell. The result is metabolic trapping: FDG accumulates intracellularly in proportion to the cell's glucose metabolic rate. The liver and kidneys are exceptions, as they express high levels of glucose-6-phosphatase, allowing FDG to be dephosphorylated and released -- which is why normal hepatocytes show only moderate FDG accumulation.
Warburg Effect
The basis for oncologic FDG PET lies in the Warburg effect: malignant cells preferentially use aerobic glycolysis for energy production, even in the presence of adequate oxygen. This metabolic reprogramming is accompanied by upregulation of GLUT-1 transporters and hexokinase, driving higher FDG uptake in most tumors compared with surrounding normal tissue.
Patient Preparation
Standard Protocol
Proper patient preparation is essential for a high-quality FDG PET study. Patients must fast for a minimum of 4 to 6 hours before the exam to lower circulating insulin and blood glucose levels. Blood glucose is checked before injection and should ideally be below 150 to 200 mg/dL. Hyperglycemia causes competitive inhibition of FDG uptake in tumors (glucose molecules compete with FDG for transport and phosphorylation), while elevated insulin shunts FDG into skeletal muscle, degrading image quality. Diabetic patients require specific protocols, typically scheduled in the morning with short-acting insulin held. Oral hydration is encouraged to promote urinary excretion and reduce bladder activity. Patients should avoid strenuous exercise for 24 hours before the scan to minimize muscle uptake, and the environment should be kept warm for 15 to 30 minutes before and during the uptake period to prevent brown fat activation. Most medications are not withheld, though metformin may cause increased bowel uptake. The standard uptake period is 60 minutes post-injection, during which the patient rests in a quiet, warm, dimly lit room to minimize physiologic muscle and brown fat uptake.
Injection Technique
The typical adult dose is 370 to 555 MBq (10 to 15 mCi), administered through an indwelling IV catheter followed by a saline flush. Paravenous injection (extravasation) must be avoided, as it causes local FDG accumulation and may produce lymph node uptake along the drainage pathway, compromising the study. Injection in the arm ipsilateral to known pathology -- for example, in a patient with breast cancer -- should also be avoided because it may cause axillary node artifact.
Normal Biodistribution
High-Uptake Organs
The brain shows the highest physiologic FDG uptake because glucose is its primary fuel source, with uptake predominantly in the gray matter. The heart has variable uptake depending on fasting state; proper fasting suppresses myocardial FDG metabolism. The liver demonstrates moderate, homogeneous uptake and serves as the reference standard for many response assessment criteria. The kidneys, ureters, and bladder show activity due to renal excretion of FDG, and intense urinary activity can obscure pelvic lesions.
Moderate Uptake
The tonsils and adenoids show moderate symmetric uptake due to their lymphoid tissue, especially in younger patients. Salivary glands demonstrate mild to moderate uptake. The GI tract has variable bowel uptake related to smooth muscle activity, lymphoid tissue, and swallowed secretions. Bone marrow shows diffuse low to moderate uptake that increases after chemotherapy, G-CSF administration, or in the setting of anemia. The thymus is commonly FDG-avid in children and young adults, and thymic rebound uptake is frequently seen after chemotherapy.
Low Uptake
Skeletal muscle has low uptake at rest but shows increased uptake with recent exercise, muscular tension, or insulin administration. Fat tissue shows negligible uptake, with the important exception of brown adipose tissue. Lung parenchyma has very low uptake and serves as a background reference in some protocols.
Common Pitfalls and Artifacts
Brown Fat Uptake
Metabolically active brown adipose tissue (BAT) is one of the most common sources of false-positive FDG uptake. It appears as symmetric, bilateral uptake in cervical, supraclavicular, axillary, paravertebral, and mediastinal fat. The key to distinguishing it from lymphadenopathy is CT correlation: brown fat uptake corresponds to fat density on CT, not soft tissue density. Brown fat activation is more common in young patients, women, cold weather, and individuals with low BMI. Mitigation strategies include maintaining a warm environment, providing warm blankets, and in some cases administering anxiolytics (diazepam) or beta-blockers (propranolol).
Muscle Uptake
Various patterns of muscular FDG uptake can mimic pathology. Laryngeal muscle uptake results from talking during the uptake period. Extraocular muscle uptake occurs with eye movement. Neck and shoulder muscle uptake reflects tension or head turning. Diaphragmatic crural uptake comes from breathing. Diffuse skeletal muscle uptake results from insulin administration, recent exercise, or hyperinsulinemia. Prevention centers on patient silence and relaxation during the uptake period and proper preparation.
Inflammatory and Infectious Uptake
Activated inflammatory cells -- macrophages, neutrophils, and lymphocytes -- avidly take up FDG. Post-surgical inflammation typically takes 4 to 6 weeks to subside sufficiently for accurate restaging. Radiation therapy effects, including radiation pneumonitis and esophagitis, necessitate waiting 8 to 12 weeks post-treatment. Granulomatous diseases such as sarcoidosis, tuberculosis, and fungal infections are characteristically FDG-avid. Atherosclerotic plaque inflammation also shows uptake. Importantly, FDG PET alone cannot reliably distinguish infection or inflammation from malignancy.
Post-Treatment Changes
The flare phenomenon refers to transiently increased FDG uptake early after effective therapy, caused by tumor cell death and the resulting inflammatory response. Radiation pneumonitis produces geometric FDG uptake that conforms to the radiation field boundaries. Bone marrow stimulation after G-CSF or chemotherapy causes diffuse increased marrow uptake; waiting 2 to 4 weeks after G-CSF is recommended before scanning. Thymic rebound, the re-expansion of thymic tissue after chemotherapy, produces triangular anterior mediastinal uptake that is especially common in young patients. Post-biopsy changes can cause focal uptake at recent biopsy sites.
Physiologic Variants
Several physiologic variants can pose interpretive challenges. Unilateral vocal cord paralysis causes asymmetric uptake in the functioning contralateral cord due to compensatory hyperactivity. Colonic uptake is variable and may be segmental; it can be physiologic (smooth muscle activity) or pathologic (polyps, cancer), sometimes requiring colonoscopic correlation. Endometrial uptake is physiologic during menstruation and ovulation. Renal collecting system and bladder activity can be managed with diuretic and voiding protocols. Diffuse thyroid uptake may indicate thyroiditis and should prompt thyroid function testing. Focal thyroid uptake carries approximately a 33% risk of malignancy and warrants thyroid ultrasound with possible biopsy.
Technical Artifacts
Paravenous injection causes FDG infiltration at the injection site with proximal lymph node uptake along the drainage pathway. Attenuation correction artifacts arise from metallic implants or respiratory misregistration between PET and CT acquisitions. Patient motion produces blurring and PET-CT misregistration.
SUV Interpretation
Standardized Uptake Value
The standardized uptake value (SUV) is a semi-quantitative measure of FDG uptake, calculated as tissue activity concentration divided by the injected dose normalized to body weight. SUVmax is the single highest voxel value within a region and is the most commonly reported metric; it is reproducible but susceptible to statistical noise. SUVmean is the average value within a region of interest and is more stable but requires consistent ROI delineation. SUVpeak is the average within a 1 cm^3 sphere centered on the hottest region and is recommended by the PERCIST response criteria. SULpeak normalizes to lean body mass rather than total body weight, reducing variability in obese patients.
Factors Affecting SUV
Multiple factors influence SUV measurements and must be controlled for meaningful serial comparisons. Uptake time affects values because longer uptake increases tumor SUV, which is why standardization at 60 minutes is critical. Hyperglycemia lowers tumor SUV by competitive inhibition. Patient body weight inflates SUV values normalized to total weight (SUVbw), particularly in obese patients. Reconstruction parameters and scanner type introduce variability across institutions. The partial volume effect causes artificially low SUV in small lesions because the activity is averaged with surrounding tissue. Dose extravasation at the injection site reduces the effective circulating dose and lowers measured SUV.
| Factor | Effect on Tumor SUV | Mitigation |
|---|---|---|
| Uptake time (>60 min) | Increases SUV | Standardize at 60 ± 5 min |
| Hyperglycemia | Decreases tumor SUV | Fast 4–6 h; check glucose <200 mg/dL |
| Body weight normalization | SUVbw inflated in obese patients | Use SULpeak (lean body mass) |
| Partial volume effect | Decreases SUV in lesions <2 cm | Note lesion size; use SUVpeak |
| Dose extravasation | Decreases all SUV values | Verify IV patency; saline flush |
| Scanner/reconstruction differences | Variable | Use same scanner/protocol for follow-up |
<image>A diagram illustrating the mechanism of FDG uptake and metabolic trapping in a cell. Show FDG entering through GLUT-1 transporter alongside glucose. Inside the cell, show hexokinase phosphorylating both glucose and FDG. Glucose-6-phosphate continues through glycolysis, but FDG-6-phosphate is trapped (blocked arrow indicating it cannot be further metabolized or dephosphorylated). Include a comparison between normal cells and cancer cells showing upregulated GLUT-1 and hexokinase in the cancer cell (Warburg effect).</image>
<image>A composite image showing common FDG PET/CT pitfalls. Panel A: bilateral symmetric cervical and supraclavicular brown fat uptake with corresponding fat density on CT. Panel B: diffuse skeletal muscle uptake from hyperinsulinemia. Panel C: post-radiation pneumonitis with geometric FDG uptake conforming to the radiation field. Panel D: thymic rebound in a young patient after chemotherapy showing triangular anterior mediastinal uptake. Panel E: focal thyroid uptake requiring further evaluation with ultrasound.</image>
<image>A normal FDG PET/CT maximum intensity projection (MIP) image with labeled anatomy showing expected physiologic biodistribution: intense brain cortical uptake, variable myocardial uptake, moderate liver uptake, renal excretion with urinary bladder activity, mild tonsillar and salivary gland uptake, and low-level bone marrow activity. Annotate with typical SUV ranges for each organ.</image>
Clinical Pearls
Blood glucose must be checked before FDG injection. Hyperglycemia competitively inhibits tumor FDG uptake and causes diffuse muscle uptake, degrading study quality and potentially leading to false-negative results.
Brown fat uptake is the most common pitfall on FDG PET. It should never be mistaken for lymph node metastases -- always correlate with CT to confirm fat density at sites of uptake, and look for the characteristic symmetric bilateral pattern.
Focal thyroid uptake on FDG PET has approximately a 33% risk of malignancy. Thyroid ultrasound and possible fine-needle aspiration biopsy should be recommended.
Timing of restaging scans after treatment is critical: wait at least 8 to 12 weeks after radiation therapy and 4 to 6 weeks after surgery to minimize false-positive inflammatory uptake.
The liver serves as the internal reference standard for many response criteria, including the Deauville scale for lymphoma and PERCIST for solid tumors. Liver SUV should be noted on every study.
FDG is not specific for cancer. Infection, inflammation, granulomatous disease, and post-treatment changes are all FDG-avid. Clinical context is essential for accurate interpretation.
Some cancers have inherently low FDG avidity and may produce false-negative results: well-differentiated hepatocellular carcinoma, mucinous tumors, renal cell carcinoma, low-grade neuroendocrine tumors, and prostate adenocarcinoma. Knowing the limitations of FDG PET is as important as knowing its strengths.
References
- Boellaard R, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328-354.
- Delbeke D, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47(5):885-895.
- Cook GJR, et al. Pitfalls and artifacts in FDG PET and PET/CT. Semin Nucl Med. 2004;34(2):122-133.
- Basu S, et al. Fundamentals of PET and PET/CT imaging. Ann N Y Acad Sci. 2011;1228:1-18.
